|
⚲
|
| Keyboard |
| Decheng Capital LLC
✚
|
|
|---|---|
| CRD # | 293073 |
| SEC # | 801-118587 |
| CIK # | 0002010850 |
| AUM | 2,728.2 M (2026-03-31) |
| Employees | 23 (57% Investors, 0% Brokers) |
| Phone | 650-382-5514 |
| Address | 3000 Sand Hill Road Menlo Park, CA 94025 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| CG Oncology Inc | 431.2 | ||
| Panacea Acquisition Corp | 111.3 | ||
| Upstream Bio Inc | 24.5 | ||
| Aclaris Therapeutics Inc | 15.2 | ||
| Aardvark Therapeutics Inc | 14.8 | ||
| Lyell Immunopharma Inc | 13.9 | ||
| Newamsterdam Pharma Co NV | 10.4 | ||
| Arcus Biosciences Inc | 10.3 | ||
| Revolution Medicines Inc | 9.1 | ||
| Equillium Inc | 8.9 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Decheng Capital Global Life Sciences Fund V-A LP | [2025-03-31] | 452.0 M | 32.9 M |
| Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Decheng Capital Global Life Sciences Fund V-B LP | [2025-03-31] | 452.0 M | 22.0 M |
| Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Decheng Capital Global Life Sciences Fund V LP | [2025-03-31] | 452.0 M | 449.3 M |
| Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | Decheng Capital Global Healthcare Fund Master LP | [2021-03-31] | 139.0 M | 228.2 M |
| Filed 2025-10-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Decheng Capital Global Life Sciences Fund IV LP | [2021-03-31] | 825.3 M | |
| Offered $650,000,000 · Filed 2020-12-15 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $650,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Decheng Capital China Life Sciences USD Fund III LP | [2018-07-19] | 625.9 M | |
| Offered $450,000,000 · Filed 2018-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $450,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Decheng Capital China Life Sciences USD Fund II LP | [2018-07-19] | 480.6 M | |
| Offered $250,000,000 · Filed 2015-08-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $250,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Decheng Capital China Life Sciences USD Fund I LP | [2018-07-19] | 123.0 M | 78.9 M |
| Offered $125,000,000 · Filed 2013-06-05 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining $1,998,247 · Duration More than one year · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 2.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 2.7 |
| By Discretionary | ||
| Discretionary | 10 | 2.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 2.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.6 | |
| United States Persons | 0.2 | |
| Total | 10 | 2.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Xiangmin Cui | Director, Executive Officer, Promoter | 14 | 2 | |
| Bay City Capital LLC | Director | 2 | 2 | |
| Decheng Capital SV LLC | Executive Officer | 2 | 2 | |
| Decheng Capital Global Healthcare GP LLC | Executive Officer | 2 | 2 | |
| Decheng Capital Management IV Cayman LLC | Promoter | 1 | 1 | |
| Yuheng Qiu | Director | 1 | 1 | |
| DT Capital Management Company Limited | Director | 1 | 1 | |
| Fengying Yu | Promoter | 1 | 1 | |
| Decheng Capital China Management I Cayman LLC | Promoter | 1 | 1 | |
| Xiangmin Min | Director | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0002010850] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Comparable Firms | State | AUM |
|---|---|---|
|
Pointer Management LLC
✚
|
TN | 2,790.9 M |
|
Serone Capital Management LLP
✚
|
2,731.1 M | |
|
Sound Point Commercial Real Estate Finance LLC
✚
|
NY | 2,723.4 M |
|
Mangrove Partners IM LLC
✚
|
CT | 2,705.9 M |
|
1Sharpe Capital LLC
✚
|
CA | 2,700.3 M |
|
Hook Mill Capital Partners LP
✚
|
NY | 2,698.0 M |
|
Advanced Portfolio Management LLC
✚
|
NY | 2,697.1 M |
|
Gobi Capital LLC
✚
|
CA | 2,689.4 M |
|
Cadian Capital Management LP
✚
|
NY | 2,680.0 M |
|
Eversept Partners LP
✚
|
NY | 2,651.0 M |